<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551833</url>
  </required_header>
  <id_info>
    <org_study_id>supraclavicular block</org_study_id>
    <nct_id>NCT04551833</nct_id>
  </id_info>
  <brief_title>Tramadol Versus Dexamethasone as Adjuvant to Levobupivacaine Supraclavicular Block</brief_title>
  <official_title>Tramadol Versus Dexamethasone as Adjuvant to Levobupivacaine Under Ultrasound Guided Supraclavicular Block of Forearm Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's aim will be to compare the efficacy of perineural tramadol and&#xD;
      dexamethasone added to levobupivacaine in prolonging postoperative analgesia in patient&#xD;
      undergoing open reduction and internal fixation for forearm fractures.&#xD;
&#xD;
      Primary outcome: duration of postoperative analgesia. Secondary outcome: include [The&#xD;
      anesthesia onset time, total rescue analgesic consumption in the 1st 24-hour and the presence&#xD;
      of complications and side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Strategies to prolong brachial plexus nerve blocks analgesia beyond the pharmacological&#xD;
      duration of the local anaesthetic used include placement of indwelling perineural catheters&#xD;
      to allow prolonged infusion or the co-administration of adjuvants such as epinephrine, alpha&#xD;
      2 agonists (as clonidine and dexmedetomidine), midazolam, or the corticosteroid dexamethasone&#xD;
      .&#xD;
&#xD;
      Dexamethasone improves the quality and duration of peripheral nerve block over local&#xD;
      anaesthetic alone. This is thought to be mediated by attenuating the release of inflammatory&#xD;
      mediators, reducing ectopic neuronal discharge, and inhibiting potassium channel-mediated&#xD;
      discharge of nociceptive C-fibres .&#xD;
&#xD;
      Tramadol is a unique opioid with two modes of action for inhibition of pain, an opioid action&#xD;
      mediated by the μ receptor and a non-opioid action mediated by α-2-adrenergic and&#xD;
      serotoninergic activity .The monoaminergic activity of tramadol inhibits the descending pain&#xD;
      pathways, resulting in suppression of nociceptive transmission at the spinal level . Tramadol&#xD;
      also exhibits local anaesthetic properties by blocking K+ channels .Many studies have&#xD;
      characterized the effects of tramadol as an adjuvant to local anaesthetic in brachial plexus&#xD;
      block .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of postoperative analgesia in hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Duration of postoperative analgesia in hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The anesthesia onset time</measure>
    <time_frame>20 minutes</time_frame>
    <description>Anasthesia onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of Paracetamol as rescue analgesia in mg</measure>
    <time_frame>24 hours</time_frame>
    <description>Rescue Analgesia in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of complications and side effects</measure>
    <time_frame>24 hours</time_frame>
    <description>complications and side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Regional Anesthesia</condition>
  <arm_group>
    <arm_group_label>Group (T) : 30 patients (Tramadol group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 1.5 mg/kg Tramadol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (D) : 30 patients (Dexamethasone group):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 8mg of Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>Tramadol versus Dexamethasone as adjuvant to Levobupvacain</description>
    <arm_group_label>Group (D) : 30 patients (Dexamethasone group):</arm_group_label>
    <arm_group_label>Group (T) : 30 patients (Tramadol group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologist physical status I-II patients older than 18years&#xD;
             and scheduled for internal fixation for forearm fractures&#xD;
&#xD;
          -  Both sexes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known allergy to the study drugs&#xD;
&#xD;
          -  Skin infection at site of needle puncture&#xD;
&#xD;
          -  Significant organ dysfunction&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Epilepsy and psychiatric illness that would interfere with perception and assessment&#xD;
             of pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Esraa Gamal Abdel Nasser, Resident</last_name>
    <phone>+201069721653</phone>
    <email>esraagamalabdelnasser@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Hassan Bakri, Professor</last_name>
    <phone>+201066356375</phone>
    <email>mhbakri@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Zhao WL, Ou XF, Liu J, Zhang WS. Perineural versus intravenous dexamethasone as an adjuvant in regional anesthesia: a systematic review and meta-analysis. J Pain Res. 2017 Jul 4;10:1529-1543. doi: 10.2147/JPR.S138212. eCollection 2017. Review.</citation>
    <PMID>28740419</PMID>
  </reference>
  <reference>
    <citation>Pehora C, Pearson AM, Kaushal A, Crawford MW, Johnston B. Dexamethasone as an adjuvant to peripheral nerve block. Cochrane Database Syst Rev. 2017 Nov 9;11:CD011770. doi: 10.1002/14651858.CD011770.pub2. Review.</citation>
    <PMID>29121400</PMID>
  </reference>
  <reference>
    <citation>Nagpal V, Rana S, Singh J, Chaudhary SK. Comparative study of systemically and perineurally administered tramadol as an adjunct for supraclavicular brachial plexus block. J Anaesthesiol Clin Pharmacol. 2015 Apr-Jun;31(2):191-5. doi: 10.4103/0970-9185.155147.</citation>
    <PMID>25948899</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Esraa Gamal</investigator_full_name>
    <investigator_title>Resident of Anesthesia, ICU and Pain management</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

